-
ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)
Monday, June 24, 2013 - 3:16pm | 935Read More...Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...
-
Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)
Wednesday, September 5, 2012 - 3:34pm | 581Read More...Here is a quick look three top-performing biotech stocks with a consensus recommendation of analysts of Strong Buy. They are Medivation (NASDAQ: MDVN), Synageva BioPharma (NASDAQ: GEVA) and Optimer Pharmaceuticals (NASDAQ: OPTR). Medivation This San Francisco-based biopharmaceutical company...
-
Best Biotech Stocks of 2011
Tuesday, December 27, 2011 - 11:39am | 830Read More...Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...
-
Bounce-Back Kings: 9 Stocks Up More Than 30% in the Past Month
Wednesday, September 14, 2011 - 8:23am | 841Read More...These nine stocks have bounced back from sell-offs in August, and their share prices are more than 30% higher than a month ago. Clearwire (NASDAQ: CLWR) shares are trading more than 60% higher than a month ago, despite pulling back more than 17% in the past week. Recent buyout rumors and the halt...
-
UPDATE: Citadel Securities Initiates Coverage on Optimer Pharmaceuticals
Monday, August 8, 2011 - 7:42am | 95Read More...Citadel Securities has published a report on Optimer Pharmaceuticals initiating coverage on the biopharm company. In the report, Citadel Securities wrote, "Although we view Dificid as a best-in-class treatment for Clostridium difficile (C. diff) associated infection, we believe competition from...
-
Oppenheimer Raises PT On Optimer Pharmaceuticals To $19
Monday, June 13, 2011 - 7:31am | 26Read More...Oppenheimer has raised the price target on Optimer Pharmaceuticals (NASDAQ: OPTR) from $17 to $19 and maintains its Outperform rating.
-
Jefferies Maintains DIFICID Sales Estimates
Tuesday, May 31, 2011 - 7:18am | 146Read More...Jefferies is maintaining its “modest/below-consensus sales estimates” on DIFICID, a new treatment for Clostridium difficileassociated diarrhea from Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR). “We maintain our U.S. sales estimates of ~$8M in 2011 (vs. consensus of ~$10M), ~$46M in 2012 (cons. ~$...
-
Oppenheimer Reports on Optimer Pharmaceuticals (OPTR)
Friday, May 6, 2011 - 9:25am | 178Read More...Oppenheimer released a report on Optimer Pharmaceuticals (NASDAQ: OPTR) earlier today. In the report, Oppenheimer was bullish on the pharmaceutical company. Oppenheimer writes, “OPTR reported 1Q11 EPS of $1.04, above our ($0.36) EPS estimate, driven by a one-time upfront licensing payment from...
-
Oppenheimer Raises PT On Optimer Pharmaceuticals To $17
Wednesday, April 6, 2011 - 7:21am | 26Read More...Oppenheimer has raised the price target on Optimer Pharmaceuticals (NASDAQ: OPTR) from $14 to $17 and maintains its Outperform rating.
-
Bank of America Upgrades Optimer Pharmaceuticals To Buy, PT To $17
Monday, April 4, 2011 - 8:41am | 29Read More...Bank of America has upgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Neutral to Buy and has raised the price target from $14 to $17.
